Short Interest in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Expands By 71.6%

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) saw a significant increase in short interest in February. As of February 28th, there was short interest totalling 182,800 shares, an increase of 71.6% from the February 13th total of 106,500 shares. Currently, 2.2% of the shares of the company are sold short. Based on an average trading volume of 2,260,000 shares, the short-interest ratio is currently 0.1 days.

Insider Activity

In other Cyclacel Pharmaceuticals news, CEO David E. Lazar sold 194,628,820 shares of the stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $0.03, for a total transaction of $5,838,864.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 23.97% of the stock is currently owned by corporate insiders.

Cyclacel Pharmaceuticals Trading Down 2.2 %

CYCC stock traded down $0.01 during midday trading on Friday, hitting $0.30. The company’s stock had a trading volume of 92,544 shares, compared to its average volume of 1,210,063. The company has a market cap of $1.87 million, a PE ratio of -0.03 and a beta of 0.28. Cyclacel Pharmaceuticals has a 12 month low of $0.29 and a 12 month high of $4.00. The firm’s 50-day moving average is $0.35 and its 200-day moving average is $0.57.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on Cyclacel Pharmaceuticals in a research note on Saturday. They issued a “sell” rating on the stock.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.